Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women
- PMID: 17785037
- DOI: 10.1258/175404507781605622
Continuous combined hormone replacement therapy relieves climacteric symptoms and improves health-related quality of life in early postmenopausal women
Abstract
Objective: Hormone replacement therapy (HRT) relieves menopausal symptoms but its effect on health related quality of life (HRQoL) is uncertain. The aim of this study was to assess the effect of three dose regimens of continuous combined HRT, consisting of estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) on HRQoL in early postmenopausal women (last menstrual period 1-3 years before study entry).
Study design: This was a 52-week, randomized, double-blind, multinational study comparing E2V (1 mg or 2 mg) plus MPA (2.5 mg or 5 mg) in different dose combinations. The intention-to-treat population comprised 459 women (average age 51.5 years).
Main outcome measures: HRQoL was assessed by the Women's Health Questionnaire (WHQ), the 15D Questionnaire and a visual analogue scale (VAS).
Results: There were improvements on eight of the nine domains of the WHQ with all dose regimens during the first 12 weeks (P<0.0001) and an improvement in the remaining domain (menstrual symptoms) with the lower-dose regimens (P<0.05). These initial improvements in HRQoL were then maintained or augmented over the remainder of the study (P<0.0001 for change from baseline at 52 weeks for all domains and dose regimens). Mean 15D total score had improved meaningfully and significantly by 12 weeks (P<0.0001 versus baseline) in all treatment groups and this improvement was maintained thereafter. This improvement in 15D total score was most marked among previous non-users of HRT (P<0.05 versus previous users). VAS scores recorded significant (P<0.05) reductions in hot flushes, sweating and sleep disturbances in all groups after week 1 and highly significant (P<0.0001) relief of all climacteric symptoms at week 52.
Conclusion: Continuous combined HRT was associated with pronounced improvement of vasomotor symptoms and HRQoL in this population of early postmenopausal women.
Similar articles
-
Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.Menopause Int. 2007 Sep;13(3):124-31. doi: 10.1258/175404507781605596. Menopause Int. 2007. PMID: 17785038 Clinical Trial.
-
Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women.Maturitas. 2005 Feb 14;50(2):91-7. doi: 10.1016/j.maturitas.2004.04.006. Maturitas. 2005. PMID: 15653005 Clinical Trial.
-
[Acceptability of continuous combined versus cyclical HRT: a French multicentric randomized clinical study].Gynecol Obstet Fertil. 2005 Jul-Aug;33(7-8):498-504. doi: 10.1016/j.gyobfe.2005.04.024. Gynecol Obstet Fertil. 2005. PMID: 16005674 Clinical Trial. French.
-
Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.Climacteric. 2003 Aug;6 Suppl 2:24-32. Climacteric. 2003. PMID: 14669841 Review.
-
Added benefits of drospirenone for compliance.Climacteric. 2005 Oct;8 Suppl 3:28-34. doi: 10.1080/13697130500330309. Climacteric. 2005. PMID: 16203653 Review.
Cited by
-
Effect of Soy Milk Consumption on Quality of Life in Iranian Postmenopausal Women.J Family Reprod Health. 2015 Jun;9(2):93-100. J Family Reprod Health. 2015. PMID: 26175764 Free PMC article.
-
Progesterone, reproduction, and psychiatric illness.Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:108-126. doi: 10.1016/j.bpobgyn.2020.06.001. Epub 2020 Jun 18. Best Pract Res Clin Obstet Gynaecol. 2020. PMID: 32723604 Free PMC article. Review.
-
Menopausal symptoms.BMJ Clin Evid. 2011 Jun 15;2011:0804. BMJ Clin Evid. 2011. PMID: 21696644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical